Metabolic Health Archives - Page 28 of 54

Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men

J. McEneny; P. A. McPherson; A. McGinty; S. S. Hull; D. R. McCance; I. S. Young Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men Ann Clin Biochem
Cholesterol

A. D. Miras; B. Pérez-Pevida; M. Aldhwayan; A. Kamocka; E. R. McGlone; W. Al-Najim; H. Chahal; R. L. Batterham; B. McGowan; O. Khan; V. Greener; A. R. Ahmed; A. Petrie; S. Scholtz; S. R. Bloom; T. M. Tan Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol
Insulin Resistance & Diabetes

W. P. Martin; Y. H. D. Chuah; M. Abdelaal; A. Pedersen; D. Malmodin; S. Abrahamsson; M. Hutter; C. Godson; E. P. Brennan; L. Fändriks; C. W. le Roux; N. G. Docherty Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease Front Endocrinol (Lausanne)
Chronic Kidney Disease Genetics

C. Le Roux; A. Aminian; R. Batterham; D. Hesse; C. Jensen; B. McGowan; A. Pakseresht; G. Rigas Sydney; F. Rubino; S. Taheri; et al. Weight loss outcomes with semaglutide 2.4 mg in moderate or severe obesity in step 1 and 2 Obesity (Silver Spring, Md.)
Insulin Resistance & Diabetes

C. Le Roux; A. Astrup; K. Fujioka; F. L. Greenway; A. Halpern; M. Krempf; D. C. Lau; R. V. Ortiz; J. Wilding; C. B. Jensen; et al. Liraglutide 3.0 mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the scale obesity and prediabetes randomized, double-blind, placebo-controlled 56-week trial Endocrine reviews. Conference: 96th annual meeting and expo of the endocrine society, ENDO 2014. Chicago, IL united states. Conference start: 20140621. Conference end: 20140624. Conference publication: (var.pagings)

C. W. Le Roux; M. Davies; J. P. Frias; P. N. Laursen; I. Lingvay; S. Machineni; A. Varbo; J. P. Wilding; S. O. Wallenstein; L. Perreault Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial Obesity facts
Metabolic Syndrome